Drug Database
Back to search

Belgium· BE-AMP-SAM185613-00

Wellvone 750 mg/5 ml

A atovaquone product containing atovaquone, registered in Belgium by GlaxoSmithKline Pharmaceuticals. The same ATC class is registered in 11 of our 19 countries.

ATC P01AX06

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedWellvone 750 mg/5 mlATCP01AX06REGISTER NO.BE-AMP-SAM185613-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about atovaquoneAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Atovaquone is registered in 11 of 19 countries.

Countries holding a registration under ATC P01AX06 (atovaquone), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 5 of them publish a price we can compare per daily dose
Search atovaquone products by name

Atovaquone · ATC P01AX06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Franceprice
  • Germany
  • Netherlands
  • Norwayprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Atovaquone
Manufacturer
GlaxoSmithKline Pharmaceuticals
Country
Belgium (BE)
ATC code
P01AX06
ATC class
Atovaquone
Defined daily dose
1.5 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    1420090

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

182 interactions on record for atovaquone.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check atovaquone against other medicinesHow interaction checks work

Atovaquone · interactions on record

182 records

  • 8 severe
  • 32 moderate
  • 4 minor
  • 133 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • EfavirenzJ05AG03severe
  • PexidartinibL01EX15severe

5 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Atovaquone in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atovaquone products

Authorised across Europe · EMA

The same active substance is authorised in 12 EEA countries. Names it is sold under:

  • Germany · Atovaquon Glenmark, Wellvone
  • Denmark · Atovaquone Glenmark
  • Spain · Atovacuona Glenmark, Wellvone
  • France · Atovaquone Biogaran, Wellvone
  • United Kingdom (Northern Ireland) · Atovaquone Amarox, Atovaquone Glenmark Pharmaceuticals Europe
  • Greece · Atovaquone Vocate, Wellvone
  • Italy · Atovaquone Glenmark, Wellvone
  • Luxembourg · Wellvone
  • Netherlands · Atovaquon Glenmark, Wellvone
  • Norway · Atovaquone Glenmark
  • Portugal · Atovaquona Kabi, Wellvone
  • Sweden · Atovaquone Glenmark, Wellvone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9edffbcc-a0a0-4f3f-a16e-6ee0cae979ec
GET /v1/drugs/9edffbcc-a0a0-4f3f-a16e-6ee0cae979ec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oral suspension",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Wellvone 750 mg/5 ml",
  "name_fr": "Wellvone 750 mg/5 ml",
  "name_nl": "Wellvone 750 mg/5 ml",
  "amp_code": "SAM185613-00",
  "strengths": [
    "750.0000",
    "50.0000",
    "10.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Atovaquone",
    "Benzyl Alcohol",
    "Saccharin Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Atovaquone",
  "authorisation_numbers": [
    "BE185613"
  ]
}
API referenceMCP serverPlans

See everything about atovaquone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console